User:Isabela de Aquino Zogbi/Sandbox1
From Proteopedia
(Difference between revisions)
| Line 33: | Line 33: | ||
== Disease == | == Disease == | ||
| - | Dysferlinopathies are caused by mutations in dysferlin and most of these mutations are part of aromatic/arginine stacks that hold the Dysf domain in a folded conformation <ref name="ref2"/>. LGMDs (Limb-girdle muscular dystrophies) are a group of muscular dystrophies characterized by predominant weakness and wasting of muscles of the pelvic and shoulder girdle (4). LGMD2B (Limb-girdle muscular dystrophy type 2B) is a predominantly proximal muscular dystrophy with an onset in the late teens, in which are identified mutations in the N terminus of Dysf gene that results in dysferlin-reactive amyloid fibrils in the muscle fibers, as a result of a destabilization of the protein | + | Dysferlinopathies are caused by mutations in dysferlin and most of these mutations are part of aromatic/arginine stacks that hold the Dysf domain in a folded conformation <ref name="ref2"/>. LGMDs (Limb-girdle muscular dystrophies) are a group of muscular dystrophies characterized by predominant weakness and wasting of muscles of the pelvic and shoulder girdle (4). LGMD2B (Limb-girdle muscular dystrophy type 2B) is a predominantly proximal muscular dystrophy with an onset in the late teens, in which are identified mutations in the N terminus of Dysf gene that results in dysferlin-reactive amyloid fibrils in the muscle fibers, as a result of a destabilization of the protein <ref name="ref3"> https://www.sciencedirect.com/science/article/pii/S0955067407000993 <ref/>. |
As for Miyoshi Myopathy (MM), it is a predominantly distal muscular dystrophy with early involvement of the posterior compartments of the lower limb and the disease onset is generally in the late teens with an initial involvement of the muscles of the distal lower limbs. Thus, in both diseases, muscles of the limb and girdle are primarily affected, the symptoms usually appear in the late teens, the diseases progress slowly and high levels of creatine kinase, a skeletal-muscle-specific enzyme, are detected in the serum of the patients (4). It is suggested that both diseases could be a result of the same mutations in the Dysf gene, and the phenotypic differences would be accounted for by modifier genes or other factors that could vary its expression (3). With the association of both dystrophies and dysferlin, and its known function of maintaining the integrity of the cells, it is suggested that it also plays an important role in facilitating the repair of cell membranes in skeletal tissues <ref name="ref5"/>. | As for Miyoshi Myopathy (MM), it is a predominantly distal muscular dystrophy with early involvement of the posterior compartments of the lower limb and the disease onset is generally in the late teens with an initial involvement of the muscles of the distal lower limbs. Thus, in both diseases, muscles of the limb and girdle are primarily affected, the symptoms usually appear in the late teens, the diseases progress slowly and high levels of creatine kinase, a skeletal-muscle-specific enzyme, are detected in the serum of the patients (4). It is suggested that both diseases could be a result of the same mutations in the Dysf gene, and the phenotypic differences would be accounted for by modifier genes or other factors that could vary its expression (3). With the association of both dystrophies and dysferlin, and its known function of maintaining the integrity of the cells, it is suggested that it also plays an important role in facilitating the repair of cell membranes in skeletal tissues <ref name="ref5"/>. | ||
| Line 40: | Line 40: | ||
== Gene Function and Molecular Genetics == | == Gene Function and Molecular Genetics == | ||
| - | Analyzing human fetal tissue, it was concluded that dysferlin is expressed in the earliest stages of development, in the embryonic ages of 5 to 6 weeks, which is the time where the limbs start its differentiation, which agrees with the limb dystrophies associated with the Dysf genes mutations. Also, the analysis of the amino acids sequences of the protein showed its relation with Caveolin-3, a skeletal muscle protein associated with forming caveolae. Dysferlin was associated with 7 sites of caveolin-3 binding motifs, which suggests its function with signaling caveolae functioning | + | Analyzing human fetal tissue, it was concluded that dysferlin is expressed in the earliest stages of development, in the embryonic ages of 5 to 6 weeks, which is the time where the limbs start its differentiation, which agrees with the limb dystrophies associated with the Dysf genes mutations. Also, the analysis of the amino acids sequences of the protein showed its relation with Caveolin-3, a skeletal muscle protein associated with forming caveolae. Dysferlin was associated with 7 sites of caveolin-3 binding motifs, which suggests its function with signaling caveolae functioning <ref name"ref3"/>. |
Wild Type dysferlin is degraded by ubiquitin/proteasome endoplasmic reticulum degradation systems. | Wild Type dysferlin is degraded by ubiquitin/proteasome endoplasmic reticulum degradation systems. | ||
Revision as of 17:40, 19 June 2022
Dysferlin
| |||||||||||
References
- ↑ 1.0 1.1 https://www.omim.org/entry/603009?search=dysferlin&highlight=dysferlin
- ↑ 2.0 2.1 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0013854
- ↑ 3.0 3.1 3.2 3.3 https://www.sciencedirect.com/science/article/pii/S0022283619301883
- ↑ 4.0 4.1 4.2 4.3 4.4 https://link.springer.com/article/10.1186/1472-6807-14-3
- ↑ 5.0 5.1 https://onlinelibrary.wiley.com/doi/full/10.1111/j.1600-0854.2011.01267.x
- ↑ https://www.sciencedirect.com/science/article/pii/S0005273614000108?via%3Dihub
- ↑ https://pubs.acs.org/doi/full/10.1021/bi400432f
- ↑ https://www.sciencedirect.com/science/article/pii/S0955067407000993 <ref></ref>.
As for Miyoshi Myopathy (MM), it is a predominantly distal muscular dystrophy with early involvement of the posterior compartments of the lower limb and the disease onset is generally in the late teens with an initial involvement of the muscles of the distal lower limbs. Thus, in both diseases, muscles of the limb and girdle are primarily affected, the symptoms usually appear in the late teens, the diseases progress slowly and high levels of creatine kinase, a skeletal-muscle-specific enzyme, are detected in the serum of the patients (4). It is suggested that both diseases could be a result of the same mutations in the Dysf gene, and the phenotypic differences would be accounted for by modifier genes or other factors that could vary its expression (3). With the association of both dystrophies and dysferlin, and its known function of maintaining the integrity of the cells, it is suggested that it also plays an important role in facilitating the repair of cell membranes in skeletal tissues <ref></ref>.
It is also associated with dysferlin mutations the DMAT (distal myopathy with anterior tibial onset).
Gene Function and Molecular Genetics
Analyzing human fetal tissue, it was concluded that dysferlin is expressed in the earliest stages of development, in the embryonic ages of 5 to 6 weeks, which is the time where the limbs start its differentiation, which agrees with the limb dystrophies associated with the Dysf genes mutations. Also, the analysis of the amino acids sequences of the protein showed its relation with Caveolin-3, a skeletal muscle protein associated with forming caveolae. Dysferlin was associated with 7 sites of caveolin-3 binding motifs, which suggests its function with signaling caveolae functioning <ref></ref>. Wild Type dysferlin is degraded by ubiquitin/proteasome endoplasmic reticulum degradation systems.
Both MM and LGMD2B were mapped to the same chromosomal region and it suggests that the dystrophies are given by allelic disorders, as affected people with both diseases seem to have the same haplotype, suggesting that phenotypic differences are given by differential expression driven by modifying factors.
